Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.
about
Tumor-Associated Mast Cells in Thyroid CancerFunctional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer ProgressionBroad targeting of angiogenesis for cancer prevention and therapyMetastatic mechanisms in follicular cell-derived thyroid cancerPro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic TargetsThe role of chemoattractant receptors in shaping the tumor microenvironment.Inhibition of CSF-1R supports T-cell mediated melanoma therapyBRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.Immune response in thyroid cancer: widening the boundaries.Multi-study integration of brain cancer transcriptomes reveals organ-level molecular signaturesEstablishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.miRNA expression in anaplastic thyroid carcinomas.Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.Follicular thyroid carcinoma but not adenoma recruits tumor-associated macrophages by releasing CCL15Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistanceMouse models of thyroid cancer: A 2015 update.G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancerThe immune network in thyroid cancerTrial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.The expression of tumor-associated macrophages in papillary thyroid carcinomaThrombospondin-1 Silencing Down-Regulates Integrin Expression Levels in Human Anaplastic Thyroid Cancer Cells with BRAF(V600E): New Insights in the Host Tissue Adaptation and Homeostasis of Tumor MicroenvironmentObatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosisImmune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by HrasG12V and Pten Loss.The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinomaOncogene-induced senescence as a new mechanism of disease: the paradigm of erdheim-chester disease.Treatment of distant metastases from follicular cell-derived thyroid cancerA distinct serum metabolic signature of distant metastatic papillary thyroid carcinoma.Evolving molecularly targeted therapies for advanced-stage thyroid cancers.Vascular hyperpermeability as a hallmark of phacomatoses: is the etiology angiogenesis related to or comparable with mechanisms seen in inflammatory pathways? Part II: angiogenesis- and inflammation-related molecular pathways, tumor-associated macroTranscriptional and metabolic reprogramming induce an inflammatory phenotype in non-medullary thyroid carcinoma-induced macrophages.The expression of tumor-associated macrophages in papillary thyroid carcinoma.Novel targeted therapies and immunotherapy for advanced thyroid cancers.Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity.Nonresolving macrophage-mediated inflammation in malignancy.Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.Tumor-associated macrophages promote the metastatic potential of thyroid papillary cancer by releasing CXCL8.Targeting Macrophages in Cancer: From Bench to Bedside.Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?
P2860
Q26784415-1E872412-A55E-4907-893E-025285364CE6Q26863784-D9248ABC-5817-4CDB-8475-C73F8124D8ABQ27002903-361B5964-1885-4186-9CBC-9493427B5251Q27005646-80DCCDF6-BC4D-4F4B-B5C1-AF123EF9AB03Q28076161-13A57417-6595-4D33-8958-2C219F797A9AQ33993124-B0710FC6-9695-4F65-9A30-6A07ADD027DAQ34027586-EA18E0AD-C819-4D75-9468-150946A984EEQ34103836-788D2DF0-4C50-47B5-96C1-B2712B929B95Q34310495-7BF50D81-3F1E-4411-88E1-43C3130900EFQ34916522-7284B9E1-A336-418F-84A5-943990D9C269Q35055061-31EE268A-2774-4394-9FFB-83987CD91E49Q35230925-FED29D4E-C4BB-4401-955B-12AE2986EEEAQ35832157-B0D7F43B-D99D-4F13-A887-BD6C0BF2492DQ35923375-0F621A14-6A96-4FA9-88AF-C02B5D01F0F1Q36125878-4F42CC7A-EACB-4687-85EB-377F297FA025Q36405539-43B77F32-2865-4CC4-A788-B94AAB84A31FQ36821159-090CCCA2-42D9-464D-88BC-52A068322147Q37079138-46B54606-2F34-4505-B800-65A098A1D8B1Q37079141-5FFAE426-602F-4DEA-AF99-3AC9059BD90EQ37264425-D818CCC9-75E2-45BD-8C27-FB1F4282BB65Q37353828-0E1F9B87-CBA5-4057-B8B4-7FFFD951FD11Q37376300-D8C0C172-AC70-47F3-84F1-C9C8C1EDEE02Q37486166-68A64A88-5608-4F41-A295-F2AD17A44CE2Q37712700-DF54F890-FC2D-44D8-90E4-0DABF180666EQ38225118-F8855B39-C1D3-4E9A-9684-DC7C7C395A8EQ38370352-3267D4BB-2E23-4856-946A-7B8A36B7B856Q38653990-4F8D969F-FD31-4722-A6A8-AE194824DC5EQ38754489-C5F45BCD-687C-4C1D-B20A-241FE317175CQ39173616-46F93394-081B-4C66-AAC9-BC4CA538A0A5Q40357866-89B90324-669F-41D8-950A-1474838F1699Q42929951-00408D8B-3392-4A5D-AAA8-E9305A98F42BQ49887965-7F9E59AB-AA6D-4DC9-BF1A-A0032F5E2F28Q50048634-28738555-4D3A-4C87-86A4-C07DCBAD9159Q50249667-FFC219B6-88F5-427C-B2FF-5A3042293ACCQ53099163-16A918EE-DAD5-47BC-99CD-0EA329D1C0E9Q53241152-92770AC5-FAA4-483C-8497-23E3ECBBD540Q55315292-90DB0C3C-C343-4F4A-86AA-34424EC77583Q55497094-CBF2B54C-6EFD-45B4-B560-1F83D5F7B994
P2860
Genetic and pharmacological targeting of CSF-1/CSF-1R inhibits tumor-associated macrophages and impairs BRAF-induced thyroid cancer progression.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@ast
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@en
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@nl
type
label
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@ast
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@en
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@nl
prefLabel
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@ast
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@en
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@nl
P2093
P2860
P1433
P1476
Genetic and pharmacological ta ...... ed thyroid cancer progression.
@en
P2093
Eric Pamer
James A Fagin
Jeff Knauf
Johanna A Joyce
Mabel Ryder
Matti Gild
Ronald Ghossein
P2860
P304
P356
10.1371/JOURNAL.PONE.0054302
P407
P577
2013-01-23T00:00:00Z